# OnCo record cll (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/cll/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "cll" ;
  schema:name "Chronic lymphocytic leukaemia"@en ;
  schema:description "A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."@en ;
  schema:url <https://onco.cc/cancers/cll/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1088156> ;
  schema:citation <https://jnccn.org/view/journals/jnccn/24/3/article-p68.xml>, <https://ashpublications.org/blood/article/131/25/2745/36953> ;
  onco:tag "heme" ;
  onco:related <https://onco.cc/cancers/cml/>, <https://onco.cc/cancers/hairy-cell-leukemia/>, <https://onco.cc/cancers/cmml/>, <https://onco.cc/cancers/all-leukemia/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/technologies/cytogenetics-fish/>, <https://onco.cc/technologies/bh3-profiling/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/cardio-oncology/> ;
  onco:targets <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/ror1/>, <https://onco.cc/targets/btk/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/clonoseq/>, <https://onco.cc/drugs/alemtuzumab/>, <https://onco.cc/drugs/chlorambucil/>, <https://onco.cc/drugs/fludarabine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/ofatumumab/>, <https://onco.cc/drugs/rasburicase/> ;
  onco:companies <https://onco.cc/companies/curis/>, <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/beone/>, <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/johnson-johnson/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/adaptive-biotechnologies/> ;
  onco:pathways <https://onco.cc/pathways/apoptosis-bcl2/>, <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:terms <https://onco.cc/terms/ighv-status/>, <https://onco.cc/terms/del17p-tp53/>, <https://onco.cc/terms/richter-transformation/>, <https://onco.cc/terms/mrd-negative-cr/>, <https://onco.cc/terms/tumor-lysis-syndrome/> ;
  onco:trials <https://onco.cc/trials/tai-shan6/>, <https://onco.cc/trials/nct07342478/>, <https://onco.cc/trials/nct07516093/>, <https://onco.cc/trials/apex-03/>, <https://onco.cc/trials/nct07509151/>, <https://onco.cc/trials/nct06973187/>, <https://onco.cc/trials/nct06943872/>, <https://onco.cc/trials/nct05947851/>, <https://onco.cc/trials/nct05624554/>, <https://onco.cc/trials/nct04075292/>, <https://onco.cc/trials/nct07277231/>, <https://onco.cc/trials/nct06428019/>, <https://onco.cc/trials/nct02477696/>, <https://onco.cc/trials/nct06846671/>, <https://onco.cc/trials/nct05645107/>, <https://onco.cc/trials/nct05023980/>, <https://onco.cc/trials/nct02970318/>, <https://onco.cc/trials/nct05254743/>, <https://onco.cc/trials/nct04965493/>, <https://onco.cc/trials/nct05057494/>, <https://onco.cc/trials/nct06970743/>, <https://onco.cc/trials/murano/> ;
  onco:journals <https://onco.cc/journals/blood-cancer-discovery/>, <https://onco.cc/journals/blood-cancer-journal/>, <https://onco.cc/journals/clinical-lymphoma-myeloma-and-leukemia/>, <https://onco.cc/journals/current-hematologic-malignancy-reports/>, <https://onco.cc/journals/haematologica/>, <https://onco.cc/journals/journal-of-hematology-and-oncology/>, <https://onco.cc/journals/leukemia-and-lymphoma/> ;
  onco:pipeline <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/dzd8586/>, <https://onco.cc/drugs/rocbrutinib/>, <https://onco.cc/drugs/bexobrutideg/>, <https://onco.cc/drugs/icp-248/>, <https://onco.cc/drugs/krt-232/>, <https://onco.cc/drugs/ctx112/>, <https://onco.cc/drugs/emavusertib/>, <https://onco.cc/drugs/sonrotoclax/>, <https://onco.cc/drugs/bgb-16673/>, <https://onco.cc/drugs/nemtabrutinib/>, <https://onco.cc/trials/celestial-tncll/>, <https://onco.cc/trials/cadance-304/>, <https://onco.cc/trials/bellwave-011/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/ideas/idea-mrd-guided-stop-cll/>, <https://onco.cc/ideas/idea-btk-degrader-frontline/>, <https://onco.cc/pairings/btki-plus-venetoclax-fixed-duration/>, <https://onco.cc/technologies/bh3-profiling/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/> ;
  onco:standardOfCare <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/terms/ighv-status/>, <https://onco.cc/trials/cll12/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/trials/cll14/>, <https://onco.cc/trials/cll13-gaia/>, <https://onco.cc/trials/amplify/>, <https://onco.cc/pairings/btki-plus-venetoclax-fixed-duration/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/trials/elevate-tn/>, <https://onco.cc/trials/sequoia/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/trials/sequoia/>, <https://onco.cc/terms/del17p-tp53/>, <https://onco.cc/pairings/cit-in-del17p-caution/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/trials/cll13-gaia/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/bgb-16673/>, <https://onco.cc/trials/bruin-cll-321/>, <https://onco.cc/trials/cadance-304/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/trials/transcend-cll-004/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/sonrotoclax/>, <https://onco.cc/terms/richter-transformation/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/terms/tumor-lysis-syndrome/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/pairings/btki-ibrutinib-cardiac-caution/> .